Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
NanoString Technologies›
Website
AddedFeb 19, 2024
UpdatedJun 18, 2026
NanoString Technologies

NanoString Technologies

Acquired

NanoString Technologies, Inc.: A U.S. biotech firm offering innovative solutions for molecular diagnostics and translational research.

HQ
Seattle, WA, US
Founded
2003
Loading
Overview
Compare
Fundraising
Employees
Website

NanoString Technologies - Website

An index of every page on nanostring.com, by section.

25 pages across 5 sections · Updated Jul 19, 2026·

Homepage

NanoString Technologies's front door: current positioning and top-line messaging.

brukerspatialbiology.com

Products / ServicesProducts

The products and services as NanoString Technologies markets them.

brukerspatialbiology.com/products
  • Analysis Solutionsoff-site/products/analysis-solutions
  • Ncounter Analysis Systemoff-site
  • Geomx Digital Spatial Profileroff-site
  • Cosmx Spatial Molecular Imageroff-site
  • Ncounter Assays Panelsoff-site/products/ncounter-assays-panels

ComparisonWill Leineweber and the Emma Lundberg Lab Pairing Cellscape with Live Cell Imaging to Explore Cancer Cell Migration

6 comparison pages published by NanoString Technologies.

  • Will Leineweber and the Emma Lundberg Lab Pairing Cellscape with Live Cell Imaging to Explore Cancer Cell Migrationoff-site
  • Cosmx Smi vs Xenium Superior in Situ Single Cell Performance Studyoff-site
  • Cosmx Smi vs Xenium Comparative Analysis of Breast Tissueoff-site
  • An Alternative to Qrt Pcr Assaysoff-site
  • Compare Plexset to Pcroff-site
  • Infographic Plexset vs Pcroff-site

AboutAbout Us

Company story, mission, and background as NanoString Technologies tells it.

brukerspatialbiology.com/about-us
  • Partnershipsoff-site/about-us/partnerships
  • Where We Areoff-site/about-us/where-we-are
  • Legaloff-site/about-us/legal
  • 20 Years of Innovationoff-site/about-us/20-years-of-innovation
  • Letter from the CEO September 19 2023off-site

Blog

Product updates, deep-dives, and company thinking: NanoString Technologies's 6-post archive.

brukerspatialbiology.com/blog
  • Of Inflammasome and Tauopathies in Mice and Menoff-site
  • A Strategic Attack Against Neurological Diseasesoff-site
  • Qa with Metabolic Pathways Panel Grant Winner Teresa Cardoso Delgado Ph D the Metabolomics of Non Alcoholic Fatty Liver Disease Nafldoff-site
  • What Is Regenerative Medicineoff-site
  • Pluripotent Stem Cells How to Best Use Them in Your Researchoff-site